CRISPR Therapeutics is a biopharma company translating the CRISPR-Cas9 genome-editing technology into transformative medicine to cure serious human diseases.
CRISPR Therapeutics – CRISPR-Cas9 genome-editing
CRISPR Therapeutics was created to translate CRISPR-Cas9 technology into human therapeutics. CRISPR (clustered regularly interspaced short palindromic repeats) and Cas9 (CRISPR-associated) offers significant advantages over traditional gene therapy approaches, offering the potential to cure many human genetic diseases. Indeed, Cas9 is an endonuclease that can be easily programmed with RNA to cut DNA at targeted sites within the genome. CRISPR Therapeutics has been created to develop cures to treat serious human genetic diseases. Initially exploring diseases that can be treated ex vivo, CRISPR Therapeutics aims in the longer term to also pursue serious diseases that are treated in vivo.
CRISPR Therapeutics is headquartered in Basel (Switzerland) and also operates in London (UK) and Cambridge (Massachusetts, USA). CRISPR Therapeutics is led by a highly experienced management team composed by Rodger Novak, Shaun Foy, Sven Ante Lundberg and Tyler Dylan-Hyde. Board of Directors is composed by Bradley Bolzon, Tom Woiwode, Rodger Novak and Shaun Foy. The founder team comprises high-profile experts in genome editing, stem cell biology, RNA interference, gene silencing and advanced drug delivery technologies. Scientific founders are Emmanuelle Charpentier, Craig Mello, Chad Cowan, Matthew Porteus and Daniel Anderson. CRISPR Therapeutics has been financed by Versant Ventures, a leading venture capital firm specialized in medical devices, biopharmaceuticals and other life science opportunities. CRISPR Therapeutics will establish strategic partnerships with biopharma companies interested in using its CRISPR-Cas9 system to develop treatments for serious diseases.
More about CRISPR Therapeutics : http://crisprtx.com/